Medicare will cover much of the cost for patients in the early stages of the disease, but Leqembi has safety risks and can only modestly slow cognitive decline.
What to Know About Leqembi, the Alzheimer's Drug Approved by the FDA
The New York Times - 7 Jul 2023 00:20
Medicare will cover much of the cost for patients in the early stages of the disease, but Leqembi has safety risks and can only modestly slow cognitive decline.
Share this Article
Recommended